Evidence map›Paper›PMID 41536273›Full record

ArticleACS pharmacology & translational science2026

Preclinical Evaluation of a

Naveen Kumar, Adrianna Bilinska, Elena Menéndez, Tilman Läppchen, Panagiotis Kanellopoulos, Anna Orlova, Frank Rösch, Axel Rominger, Eleni Gourni

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Evaluation of treatment efficacy of theEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Article
  3. A true theranostic pair -European journal of nuclear medicine and molecular imaging · 2026
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Naveen KumarDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern 3010, Switzerland.
Adrianna BilinskaDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern 3010, Switzerland.
Elena MenéndezDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern 3010, Switzerland.
Tilman LäppchenDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern 3010, Switzerland.ORCID https://orcid.org/0000-0002-7746-1572
Panagiotis KanellopoulosDepartment of Medicinal Chemistry, Uppsala University, Uppsala 751 83, Sweden.ORCID https://orcid.org/0000-0002-0617-3936
Anna OrlovaDepartment of Medicinal Chemistry, Uppsala University, Uppsala 751 83, Sweden.ORCID https://orcid.org/0000-0001-6120-2683
Frank RöschDepartment of ChemistryTRIGA site, Johannes GutenbergUniversity of Mainz, Mainz 55128, Germany.
Axel RomingerDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern 3010, Switzerland.
Eleni GourniDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern 3010, Switzerland.ORCID https://orcid.org/0000-0003-2198-382X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study evaluates the potential of a

Indexed as

combinationeverolimusfractionated therapeutic dosemonotherapymTOR inhibitorradiolabeled GRPR antagonists

Identifiers

PMID41536273
PMCPMC12797171

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.